| Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). | |
| | |
MedLine Citation:
|
PMID: 14688154 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Since the 1990 NIH-sponsored conference on polycystic ovary syndrome (PCOS), it has become appreciated that the syndrome encompasses a broader spectrum of signs and symptoms of ovarian dysfunction than those defined by the original diagnostic criteria. The 2003 Rotterdam consensus workshop concluded that PCOS is a syndrome of ovarian dysfunction along with the cardinal features hyperandrogenism and polycystic ovary (PCO) morphology. PCOS remains a syndrome and, as such, no single diagnostic criterion (such as hyperandrogenism or PCO) is sufficient for clinical diagnosis. Its clinical manifestations may include: menstrual irregularities, signs of androgen excess, and obesity. Insulin resistance and elevated serum LH levels are also common features in PCOS. PCOS is associated with an increased risk of type 2 diabetes and cardiovascular events. |
| | |
Authors:
|
|
Related Documents
:
|
2513454 - Pathophysiology of polycystic ovary syndrome. 9632094 - Antithyroid arthritis syndrome. 8140684 - Youssef's syndrome: an appraisal of hormonal treatment. 11120504 - Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. 7645604 - Neoplasms in proteus syndrome. 18467944 - A systematic approach to care: adult respiratory distress syndrome. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Human reproduction (Oxford, England) Volume: 19 ISSN: 0268-1161 ISO Abbreviation: Hum. Reprod. Publication Date: 2004 Jan |
Date Detail:
|
Created Date: 2003-12-22 Completed Date: 2004-08-25 Revised Date: 2009-06-26 |
Medline Journal Info:
|
Nlm Unique ID: 8701199 Medline TA: Hum Reprod Country: England |
Other Details:
|
Languages: eng Pagination: 41-7 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Clinical Trials as Topic Consensus Development Conferences as Topic Consensus Development Conferences, NIH as Topic Female Humans Hyperandrogenism / complications Insulin Resistance Luteinizing Hormone / blood Polycystic Ovary Syndrome / blood, complications*, diagnosis*, pathology Risk Factors United States |
| Chemical | |
Reg. No./Substance:
|
9002-67-9/Luteinizing Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Expression of nitric oxide synthase and effect of substrate manipulation of the nitric oxide pathway...
Next Document: Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance.